Clinical Trial Detail

NCT ID NCT02500576
Title MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.